• Raised A$3 million through a capital raise
• Issued 120 million new shares at A$0.025 per share
• Issued 60 million options with an exercise price of A$0.05 and 2-year expiry
• Funds to support expansion into European markets and set up medical cannabis manufacturing facilities

Bioxyne Limited, an Australian life sciences, pharmaceutical and consumer health products company, has received firm commitments to raise A$3 million in a capital raise. The raise was well supported by new and existing institutional shareholders and sophisticated investors, both domestic and international. The company will issue 120 million new shares at A$0.025 per share, a 2.2% discount to the 15-day volume-weighted average price. Additionally, the company will issue 60 million options on the basis of one option for every two new shares, with an exercise price of A$0.05 and a two-year expiry date. The funds will be used to support the company's expansion into European markets and the set up and certification of medical cannabis manufacturing facilities in the United Kingdom and Czechia. The funding will also enable Bioxyne to accelerate its growth strategy and deliver upon its stated revenue guidance of A$25 million for the 2025 financial year. The directors will participate in the capital raise for A$110,000, subject to shareholder approval. Alpine Capital Pty Limited acted as the sole lead manager and bookrunner to the placement.

The company has provided revenue guidance of A$25 million for the 2025 financial year.

The funds raised will support Bioxyne's expansion into European markets and the set up of medical cannabis manufacturing facilities in the UK and Czechia, enabling the company to accelerate its growth strategy.